Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) produced a 85.49% rally since recording the worst price of $5.17. Thanks to the latest 4.81% increase, it now trades at $9.59. Throughout the trading on 3/21/2019, the share price floated between $8.985 and $9.78. This company shares are 66.84% off its target price of $16 and the current market capitalization stands at $296.91M. The recent change has given its price a 42.42% lead over SMA 50 and -30.81% deficit over its 52-week high. The stock witnessed 57.21% gains, 33.75% gains and -25.08% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SYRS’s volatility during a week at 7.82% and during a month it has been found around 8.62%.

Syros Pharmaceuticals, Inc. (SYRS) Top Holders

Institutional investors currently hold around $203 million or 80.7% in SYRS stock. Look at its top three institutional owners: Fmr Llc owns $46.19 million in Syros Pharmaceuticals, Inc., which represents roughly 15.56% of the company’s market cap and approximately 22.75% of the institutional ownership. Similar statistics are true for the second largest owner, Flagship Pioneering Inc., which owns 3,204,437 shares of the stock are valued at $29.32 million. The third largest holder is Ark Investment Management Llc, which currently holds $22.52 million worth of this stock and that ownership represents nearly 7.58% of its market capitalization.

Syros Pharmaceuticals, Inc. 13F Filings

At the end of December reporting period, 33 institutional holders increased their position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by some 2,530,166 shares, 39 decreased positions by 947,661 and 12 held positions by 18,757,108. That puts total institutional holdings at 22,234,935 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 1,268,939 shares while 16 institutional investors sold out their entire positions totaling 326,099 shares.

Syros Pharmaceuticals, Inc. (SYRS) Analyst Guide

Several analysts have released their opinion on Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.86 average brokerage recommendation [T1].